CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Rosiglitazone +1 moredrug
Likely dose
Rosiglitazone 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01150981
NCT01150981Phase 2Completed
CompareCT.gov

Effect of Rosiglitazone on In-vivo Angiogenic Potential of Human Adipose Tissue

University of Massachusetts, Worcester·interventional·Posted Jun 25, 2010·Updated Mar 26, 2012

In Brief

A Phase 2 clinical trial evaluating Rosiglitazone and Placebo for Metabolic Syndrome and Insulin Resistance. Completed, enrolled 35 participants across 1 site.

Detailed Summary

Insulin resistance is a common condition that can lead to type 2 diabetes. One of the commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that rosiglitazone may work by increasing blood vessel growth in fat cells. The purpose of this research is to see if rosiglitazone also increases blood vessel growth in human fat cells. The investigators will compare results from before and after being on rosiglitazone for 6 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome, Insulin Resistance
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 25, 2010
Enrollment StartNov 1, 2006
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 16.0 years ago

Interventions

Rosiglitazonedrug

One 8mg capsule daily for 6 weeks.

Placebodrug

One capsule daily for 6 weeks.